| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloid-Lymphoid Leukemia Protein | 23 | 2022 | 72 | 2.650 |
Why?
|
| Leukemia, Myeloid, Acute | 18 | 2024 | 788 | 1.710 |
Why?
|
| Oncogene Proteins, Fusion | 10 | 2022 | 133 | 1.500 |
Why?
|
| Leukemia | 9 | 2017 | 323 | 1.470 |
Why?
|
| Histone-Lysine N-Methyltransferase | 21 | 2023 | 161 | 1.340 |
Why?
|
| DNA-Binding Proteins | 22 | 2019 | 1241 | 1.240 |
Why?
|
| Proto-Oncogenes | 14 | 2005 | 61 | 1.190 |
Why?
|
| Translocation, Genetic | 18 | 2016 | 266 | 1.130 |
Why?
|
| Neoplasm Proteins | 9 | 2013 | 540 | 1.120 |
Why?
|
| Peptide Elongation Factors | 7 | 2005 | 28 | 1.120 |
Why?
|
| Transcription Factors | 20 | 2013 | 1652 | 1.070 |
Why?
|
| Leukemia, Myeloid | 11 | 2012 | 249 | 1.050 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2017 | 447 | 0.910 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 7 | 2024 | 88 | 0.910 |
Why?
|
| Gene Expression Regulation, Leukemic | 4 | 2011 | 93 | 0.800 |
Why?
|
| Sulfonamides | 7 | 2024 | 317 | 0.800 |
Why?
|
| Azacitidine | 8 | 2024 | 146 | 0.710 |
Why?
|
| Chromosomes, Human, Pair 11 | 16 | 2003 | 106 | 0.630 |
Why?
|
| Antigens, CD34 | 2 | 2016 | 159 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2024 | 2552 | 0.600 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2019 | 157 | 0.560 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 48 | 0.540 |
Why?
|
| Anemia | 2 | 2020 | 129 | 0.520 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2024 | 395 | 0.480 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2023 | 665 | 0.480 |
Why?
|
| Transcriptional Elongation Factors | 10 | 2009 | 23 | 0.430 |
Why?
|
| Homeodomain Proteins | 3 | 2013 | 556 | 0.420 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 280 | 0.380 |
Why?
|
| Mitoxantrone | 3 | 2020 | 68 | 0.350 |
Why?
|
| Mice | 21 | 2017 | 11742 | 0.340 |
Why?
|
| Hematopoietic Stem Cells | 5 | 2019 | 299 | 0.330 |
Why?
|
| Humans | 72 | 2024 | 89073 | 0.330 |
Why?
|
| Acute Disease | 10 | 2013 | 841 | 0.300 |
Why?
|
| Myelodysplastic Syndromes | 6 | 2013 | 357 | 0.290 |
Why?
|
| Remission Induction | 9 | 2023 | 740 | 0.280 |
Why?
|
| Myeloproliferative Disorders | 3 | 2024 | 132 | 0.280 |
Why?
|
| Aging | 1 | 2011 | 716 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2018 | 10 | 0.260 |
Why?
|
| Cell Lineage | 2 | 2017 | 291 | 0.260 |
Why?
|
| Animals | 24 | 2017 | 27324 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 6 | 2013 | 44 | 0.240 |
Why?
|
| Gene Rearrangement | 7 | 2009 | 172 | 0.240 |
Why?
|
| Lymphoma, T-Cell | 3 | 2013 | 55 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2013 | 1265 | 0.230 |
Why?
|
| CD47 Antigen | 1 | 2024 | 23 | 0.230 |
Why?
|
| Aged | 22 | 2024 | 19078 | 0.230 |
Why?
|
| Coiled Bodies | 1 | 2003 | 2 | 0.220 |
Why?
|
| Neutropenia | 1 | 2024 | 216 | 0.220 |
Why?
|
| Transplantation Conditioning | 4 | 2013 | 374 | 0.220 |
Why?
|
| Transcriptional Activation | 3 | 2019 | 291 | 0.210 |
Why?
|
| Dancing | 1 | 2022 | 1 | 0.210 |
Why?
|
| Cytarabine | 3 | 2020 | 219 | 0.210 |
Why?
|
| Thrombocytopenia | 2 | 2020 | 187 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 616 | 0.210 |
Why?
|
| Lymphoma | 4 | 2012 | 265 | 0.200 |
Why?
|
| Consolidation Chemotherapy | 2 | 2018 | 23 | 0.200 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 2412 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 582 | 0.190 |
Why?
|
| Febrile Neutropenia | 1 | 2020 | 14 | 0.190 |
Why?
|
| Janus Kinase 2 | 2 | 2019 | 60 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2003 | 59 | 0.180 |
Why?
|
| Molecular Sequence Data | 9 | 2002 | 3027 | 0.180 |
Why?
|
| Amino Acid Sequence | 7 | 2002 | 2062 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 7 | 2011 | 1057 | 0.180 |
Why?
|
| Aminopyridines | 1 | 2020 | 40 | 0.170 |
Why?
|
| MicroRNAs | 3 | 2010 | 551 | 0.170 |
Why?
|
| Protein Binding | 5 | 2023 | 1487 | 0.170 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 55 | 0.170 |
Why?
|
| Triazines | 1 | 2020 | 53 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 106 | 0.170 |
Why?
|
| Male | 31 | 2024 | 42254 | 0.170 |
Why?
|
| Retroviridae | 5 | 2013 | 79 | 0.170 |
Why?
|
| Cloning, Molecular | 5 | 1997 | 646 | 0.170 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2010 | 198 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 604 | 0.160 |
Why?
|
| Female | 29 | 2024 | 46014 | 0.160 |
Why?
|
| Indazoles | 1 | 2019 | 67 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 3 | 2012 | 260 | 0.160 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2018 | 49 | 0.160 |
Why?
|
| Chromosome Deletion | 2 | 2016 | 229 | 0.160 |
Why?
|
| Pyrazines | 1 | 2019 | 94 | 0.160 |
Why?
|
| Quercetin | 1 | 2018 | 3 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 859 | 0.160 |
Why?
|
| Hematopoiesis | 1 | 2019 | 165 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 244 | 0.150 |
Why?
|
| Transfection | 4 | 2007 | 911 | 0.150 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 4 | 2023 | 131 | 0.150 |
Why?
|
| Middle Aged | 20 | 2024 | 25865 | 0.150 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 6777 | 0.150 |
Why?
|
| Cell Compartmentation | 1 | 1997 | 69 | 0.140 |
Why?
|
| Mutation | 7 | 2023 | 4132 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2011 | 726 | 0.140 |
Why?
|
| Zinc Fingers | 6 | 2010 | 58 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2016 | 111 | 0.140 |
Why?
|
| HeLa Cells | 4 | 2010 | 511 | 0.130 |
Why?
|
| Pneumonia | 2 | 2020 | 182 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 889 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2010 | 565 | 0.130 |
Why?
|
| Prognosis | 6 | 2023 | 3773 | 0.130 |
Why?
|
| Pyrimidines | 2 | 2016 | 372 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 1996 | 283 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 2007 | 125 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2016 | 150 | 0.130 |
Why?
|
| Repressor Proteins | 2 | 2013 | 423 | 0.130 |
Why?
|
| Chromosome Aberrations | 5 | 2012 | 390 | 0.130 |
Why?
|
| Patient Safety | 1 | 2018 | 216 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2017 | 471 | 0.130 |
Why?
|
| Cytokines | 1 | 2019 | 802 | 0.120 |
Why?
|
| Benzo(a)pyrene | 1 | 1994 | 5 | 0.120 |
Why?
|
| Adult | 20 | 2024 | 26508 | 0.120 |
Why?
|
| RNA Polymerase II | 2 | 2009 | 57 | 0.120 |
Why?
|
| Treatment Outcome | 8 | 2024 | 8203 | 0.120 |
Why?
|
| Recurrence | 4 | 2020 | 1140 | 0.120 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1994 | 79 | 0.120 |
Why?
|
| Arteriosclerosis | 1 | 1994 | 112 | 0.120 |
Why?
|
| RNA, Messenger | 9 | 2013 | 2011 | 0.110 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2013 | 20 | 0.110 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2013 | 3 | 0.110 |
Why?
|
| Transplantation, Homologous | 5 | 2017 | 996 | 0.110 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 63 | 0.110 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 39 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2018 | 669 | 0.110 |
Why?
|
| Aorta | 1 | 1994 | 288 | 0.110 |
Why?
|
| Cell Line, Tumor | 4 | 2012 | 2553 | 0.110 |
Why?
|
| Bronchiolitis Obliterans | 1 | 1992 | 33 | 0.100 |
Why?
|
| Apoptosis | 4 | 2010 | 1717 | 0.100 |
Why?
|
| Cell Line | 7 | 2009 | 2495 | 0.100 |
Why?
|
| Superoxide Dismutase | 1 | 2012 | 177 | 0.100 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2011 | 23 | 0.100 |
Why?
|
| Blotting, Northern | 3 | 2002 | 258 | 0.100 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2011 | 20 | 0.100 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2011 | 46 | 0.090 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 181 | 0.090 |
Why?
|
| Erythropoietin | 1 | 2011 | 88 | 0.090 |
Why?
|
| Stem Cell Transplantation | 3 | 2012 | 188 | 0.090 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 3 | 1996 | 16 | 0.090 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 173 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 1996 | 354 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2011 | 192 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 200 | 0.090 |
Why?
|
| Sequence Alignment | 2 | 2001 | 353 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 3657 | 0.090 |
Why?
|
| Epigenomics | 1 | 2011 | 103 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 314 | 0.090 |
Why?
|
| Methylation | 1 | 2011 | 268 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2010 | 162 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 1796 | 0.090 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2009 | 14 | 0.090 |
Why?
|
| Genetic Loci | 1 | 2011 | 253 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2013 | 4273 | 0.090 |
Why?
|
| Conserved Sequence | 2 | 2002 | 211 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2362 | 0.080 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2009 | 16 | 0.080 |
Why?
|
| Adolescent | 11 | 2024 | 9237 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 921 | 0.080 |
Why?
|
| Histones | 1 | 2011 | 329 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 387 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 727 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2011 | 341 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1710 | 0.080 |
Why?
|
| Blood Component Removal | 1 | 2008 | 24 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 1214 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 1429 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 948 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 275 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 108 | 0.070 |
Why?
|
| Melphalan | 2 | 2005 | 98 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 166 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2011 | 342 | 0.070 |
Why?
|
| Vidarabine | 2 | 2005 | 143 | 0.070 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2007 | 2 | 0.070 |
Why?
|
| Prevalence | 1 | 2011 | 1240 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2007 | 24 | 0.070 |
Why?
|
| Chromosome Inversion | 1 | 2007 | 47 | 0.070 |
Why?
|
| Base Sequence | 7 | 2008 | 2327 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2009 | 657 | 0.070 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 40 | 0.070 |
Why?
|
| Chromatin | 2 | 2022 | 397 | 0.070 |
Why?
|
| Bone Marrow | 3 | 2008 | 445 | 0.070 |
Why?
|
| Myosin Heavy Chains | 1 | 2007 | 91 | 0.070 |
Why?
|
| Precision Medicine | 1 | 2011 | 410 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 894 | 0.070 |
Why?
|
| Immune Complex Diseases | 1 | 2006 | 19 | 0.070 |
Why?
|
| Karyotyping | 4 | 2011 | 253 | 0.070 |
Why?
|
| Complement Factor H | 1 | 2006 | 34 | 0.070 |
Why?
|
| Meperidine | 1 | 1985 | 13 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2006 | 83 | 0.070 |
Why?
|
| Genetic Vectors | 2 | 2013 | 446 | 0.070 |
Why?
|
| Transcription, Genetic | 5 | 2009 | 1157 | 0.070 |
Why?
|
| Blood Platelets | 1 | 2006 | 150 | 0.060 |
Why?
|
| Inflammation | 1 | 2011 | 971 | 0.060 |
Why?
|
| Dioxygenases | 2 | 2019 | 76 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 1012 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 418 | 0.060 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2005 | 10 | 0.060 |
Why?
|
| DNA, Neoplasm | 6 | 1996 | 268 | 0.060 |
Why?
|
| Young Adult | 4 | 2024 | 6289 | 0.060 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 262 | 0.060 |
Why?
|
| Emergencies | 1 | 1985 | 121 | 0.060 |
Why?
|
| Kidney | 2 | 2010 | 1145 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 5 | 2009 | 956 | 0.060 |
Why?
|
| Binding Sites | 3 | 2002 | 1117 | 0.060 |
Why?
|
| Chromosome Mapping | 7 | 1996 | 1076 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2011 | 2863 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 138 | 0.060 |
Why?
|
| snRNP Core Proteins | 1 | 2003 | 9 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 507 | 0.060 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2003 | 20 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 1975 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 9003 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2018 | 1533 | 0.050 |
Why?
|
| Immunosorbent Techniques | 1 | 2002 | 13 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1363 | 0.050 |
Why?
|
| Sequence Homology | 1 | 2002 | 28 | 0.050 |
Why?
|
| Seizures | 1 | 1985 | 306 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2002 | 64 | 0.050 |
Why?
|
| Genes | 2 | 1994 | 305 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 95 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2022 | 65 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2003 | 59 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1574 | 0.050 |
Why?
|
| Serine | 1 | 2002 | 104 | 0.050 |
Why?
|
| Autoantigens | 1 | 2003 | 129 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2002 | 154 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1755 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2003 | 261 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2001 | 111 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2018 | 682 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 1940 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2002 | 463 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 69 | 0.050 |
Why?
|
| Leukopenia | 1 | 2020 | 66 | 0.050 |
Why?
|
| Cell Nucleus | 1 | 2002 | 599 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2006 | 2880 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2002 | 519 | 0.040 |
Why?
|
| Core Binding Factors | 2 | 2011 | 12 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 153 | 0.040 |
Why?
|
| Ethylnitrosourea | 2 | 2012 | 30 | 0.040 |
Why?
|
| Survival Rate | 2 | 2018 | 1889 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 975 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 1997 | 313 | 0.040 |
Why?
|
| Comorbidity | 2 | 2017 | 948 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 108 | 0.040 |
Why?
|
| RNA | 1 | 2003 | 578 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 46 | 0.040 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 78 | 0.040 |
Why?
|
| Cell Survival | 2 | 2012 | 982 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2018 | 84 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2004 | 1067 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2019 | 115 | 0.040 |
Why?
|
| Tretinoin | 1 | 2018 | 128 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2002 | 866 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 85 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 1996 | 27 | 0.040 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 151 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2000 | 443 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2018 | 225 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2017 | 20 | 0.040 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 29 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2018 | 125 | 0.040 |
Why?
|
| DNA Primers | 3 | 2008 | 543 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1997 | 68 | 0.040 |
Why?
|
| Embryonic and Fetal Development | 1 | 1997 | 72 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 434 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 372 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 272 | 0.040 |
Why?
|
| Graft vs Host Disease | 2 | 2005 | 360 | 0.040 |
Why?
|
| Child, Preschool | 5 | 1996 | 3717 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 557 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 1997 | 221 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 786 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1130 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2016 | 109 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 182 | 0.030 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1996 | 21 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1715 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 329 | 0.030 |
Why?
|
| Adenine | 1 | 2016 | 88 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1995 | 14 | 0.030 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1995 | 5 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1995 | 86 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1995 | 47 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2007 | 1768 | 0.030 |
Why?
|
| RNA, Neoplasm | 3 | 2007 | 88 | 0.030 |
Why?
|
| Piperidines | 1 | 2016 | 164 | 0.030 |
Why?
|
| Species Specificity | 1 | 1997 | 684 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 865 | 0.030 |
Why?
|
| Methylcholanthrene | 1 | 1994 | 10 | 0.030 |
Why?
|
| Microsomes | 1 | 1994 | 35 | 0.030 |
Why?
|
| Gene Library | 1 | 1994 | 133 | 0.030 |
Why?
|
| Biotransformation | 1 | 1994 | 50 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 887 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1994 | 88 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1994 | 79 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1994 | 100 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1994 | 100 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 682 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1995 | 342 | 0.030 |
Why?
|
| Radiotherapy | 1 | 1996 | 331 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1994 | 272 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1867 | 0.030 |
Why?
|
| Fetus | 1 | 1994 | 232 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 848 | 0.030 |
Why?
|
| X Chromosome | 1 | 1994 | 153 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1993 | 65 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1149 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2001 | 0.030 |
Why?
|
| Alkylating Agents | 1 | 2012 | 32 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2013 | 67 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1994 | 307 | 0.030 |
Why?
|
| Mercaptoethylamines | 1 | 2012 | 52 | 0.030 |
Why?
|
| Genetic Markers | 1 | 1993 | 478 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 3211 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2012 | 188 | 0.030 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 1 | 1992 | 24 | 0.030 |
Why?
|
| Child | 5 | 1996 | 7149 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2012 | 80 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2013 | 3374 | 0.030 |
Why?
|
| Gene Expression | 3 | 2004 | 1310 | 0.030 |
Why?
|
| Liver | 1 | 1997 | 1205 | 0.030 |
Why?
|
| Prednisone | 1 | 1992 | 258 | 0.020 |
Why?
|
| Syndrome | 1 | 1992 | 449 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2012 | 112 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2011 | 35 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 1237 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 261 | 0.020 |
Why?
|
| United States | 1 | 2024 | 6957 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 80 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 182 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 98 | 0.020 |
Why?
|
| Chromosome Banding | 3 | 1995 | 74 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 401 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2010 | 33 | 0.020 |
Why?
|
| K562 Cells | 1 | 2010 | 44 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 657 | 0.020 |
Why?
|
| Chromosome Disorders | 3 | 1995 | 115 | 0.020 |
Why?
|
| Smoking | 1 | 1994 | 620 | 0.020 |
Why?
|
| Mitogens | 1 | 2009 | 62 | 0.020 |
Why?
|
| Consensus Sequence | 2 | 2002 | 65 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 203 | 0.020 |
Why?
|
| Restriction Mapping | 3 | 1993 | 156 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2008 | 8 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2008 | 15 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2009 | 163 | 0.020 |
Why?
|
| Infant | 4 | 1996 | 3147 | 0.020 |
Why?
|
| Filgrastim | 1 | 2008 | 57 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 50 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2008 | 70 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 127 | 0.020 |
Why?
|
| Rats | 1 | 1994 | 4041 | 0.020 |
Why?
|
| Peptide Mapping | 1 | 2007 | 26 | 0.020 |
Why?
|
| Benzamides | 1 | 2008 | 237 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2007 | 57 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 343 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 178 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 283 | 0.020 |
Why?
|
| Myoclonus | 1 | 1985 | 16 | 0.020 |
Why?
|
| Hamartoma | 1 | 1985 | 34 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2005 | 85 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 3010 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2005 | 84 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 1996 | 392 | 0.020 |
Why?
|
| COS Cells | 1 | 2005 | 167 | 0.020 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2004 | 7 | 0.020 |
Why?
|
| Oncogenes | 1 | 2004 | 92 | 0.010 |
Why?
|
| Brain | 1 | 1994 | 2281 | 0.010 |
Why?
|
| DNA Probes | 2 | 1993 | 77 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 524 | 0.010 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2002 | 130 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 128 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1670 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 306 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 275 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 1990 | 0.010 |
Why?
|
| Rabbits | 1 | 2002 | 638 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2000 | 16 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1650 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1985 | 635 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2005 | 967 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 1088 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 1401 | 0.010 |
Why?
|
| Neoplasms | 1 | 1993 | 3035 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 738 | 0.010 |
Why?
|
| Teniposide | 1 | 1996 | 6 | 0.010 |
Why?
|
| Centromere | 1 | 1996 | 26 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 5466 | 0.010 |
Why?
|
| Etoposide | 1 | 1996 | 198 | 0.010 |
Why?
|
| Telomere | 1 | 1996 | 114 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1994 | 48 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 1994 | 34 | 0.010 |
Why?
|
| Codon | 1 | 1994 | 122 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 135 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1996 | 277 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 1995 | 210 | 0.010 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 1993 | 8 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 1993 | 72 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1993 | 71 | 0.010 |
Why?
|
| Introns | 1 | 1994 | 299 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1993 | 134 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 129 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1994 | 152 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1992 | 996 | 0.010 |
Why?
|
| Drosophila | 1 | 1995 | 521 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1995 | 2476 | 0.010 |
Why?
|